• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Kindred Biosciences to Present at Stifel 2021 Virtual Jaws & Paws Conference and LD Micro Invitational XI

    5/25/21 8:42:00 AM ET
    $KIN
    Major Pharmaceuticals
    Health Care
    Get the next $KIN alert in real time by email

    SAN FRANCISCO, May 25, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel 2021 Virtual Jaws & Paws Conference on June 2 and the LD Micro Invitational XI on June 8.  

    Kindred Biosciences, Inc. Logo

    Dr. Richard Chin, Chief Executive Officer, will be available for one-on-one meetings. During this time, investors will have the opportunity to discuss recent developments, study results from key therapeutic programs in development, and upcoming milestones.

    Conference Details:

    Stifel 2021 Virtual Jaws & Paws Conference

    Date: June 2, 2021

    Presentation time: 11:00–11:25a.m. ET

    Webcast URL: Click here

    LD Micro Invitational XI

    Date: June 8, 2021

    Presentation time: 1:30–1:55p.m. ET

    Register to watch the presentation: Click here

    An archived version of the above webcast will be available for 30 days on the KindredBio website.

    About Kindred Biosciences

    Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.

    For more information, visit: www.kindredbio.com  

    Contact

    Katja Buhrer

    [email protected]  

    (917) 969-3438

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-to-present-at-stifel-2021-virtual-jaws--paws-conference-and-ld-micro-invitational-xi-301298334.html

    SOURCE Kindred Biosciences, Inc.

    Get the next $KIN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KIN

    DatePrice TargetRatingAnalyst
    More analyst ratings